The New England journal of medicine
Audio Summaries

Effect of Screening with Multicancer Early-Detection Test on Late-Stage Cancer Diagnosis

Sep 23, 2026

The authors aimed to determine whether screening with a multicancer early-detection test, in addition to usual care, reduces the incidence of late-stage cancers (stage III or IV) compared to usual care alone. In a randomized controlled trial involving over 142,000 participants, they found no significant difference in the incidence rates of stage III or IV cancers between the two groups after three screening rounds. While there was a trend towards a lower incidence of stage IV cancers, the results were not conclusive, indicating the need for further follow-up.

Etuvetidigene Autotemcel for the Treatment of Wiskott-Aldrich Syndrome

Sep 23, 2026

This study investigates the efficacy and safety of etuvetidigene autotemcel (etu-cel), an autologous gene therapy, for treating Wiskott-Aldrich syndrome, a rare genetic disorder. The results indicate a high overall survival rate of 96% at both 1 and 5 years post-treatment, along with a significant reduction in severe infections and bleeding events after therapy. The findings suggest that etu-cel provides a sustained clinical benefit for patients with this condition.

Clinical Uses of Common Genetic Variants Associated with Common Diseases

Sep 23, 2026

The authors investigate why the integration of polygenic risk scores and genomic knowledge into clinical practice for common adult-onset diseases has been slow, despite advancements in genomics and the identification of numerous genetic variants associated with these conditions. They explore potential applications of these scores and pharmacogenomics in improving prevention and treatment strategies as genome sequencing becomes more accessible.

Phase 1 Study of Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma

Sep 23, 2026

This phase 1 study investigates the safety and efficacy of anitocabtagene autoleucel (anito-cel), a BCMA-directed CAR T-cell therapy, in patients with relapsed or refractory multiple myeloma who have undergone multiple prior treatments. The results indicate a high response rate (100%) with a significant proportion achieving complete response (79%), while adverse events, particularly cytokine release syndrome and neurotoxicity, were mostly mild. The findings suggest that anito-cel may be a promising treatment option for this challenging patient population.

Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy

Sep 14, 2026

This phase 3 trial investigates the efficacy of tambotatug pelitecan (Tam-Peli), an antibody-drug conjugate targeting B7-H3, in patients with relapsed small-cell lung cancer following platinum-based therapy, comparing it to topotecan. The results indicate that tambotatug pelitecan significantly improves overall survival and progression-free survival, with a higher objective response rate and fewer severe adverse events compared to topotecan. These findings suggest that tambotatug pelitecan may be a more effective treatment option for this patient population.

Outbreak of Severe Methemoglobinemia during Maritime Migration

Sep 9, 2026

The authors aimed to investigate the cause of severe acquired methemoglobinemia observed among migrants arriving in Lampedusa, Italy, since March 2024. Their study identified dermal absorption of the gasoline additive N-methylaniline from fuel-contaminated seawater as the likely culprit, affecting 82 patients, with significant health implications including high methemoglobin levels and delayed complications. The findings highlight the need for accessible methylene blue treatment and improved diagnostic capabilities in similar migration contexts.

Oveporexton for Narcolepsy Type 1 - Results from Two Phase 3 Trials

Sep 9, 2026

The authors aimed to evaluate the efficacy and safety of oveporexton, an oral orexin receptor 2-selective agonist, in treating narcolepsy type 1 through two Phase 3 trials. Results indicated that oveporexton significantly improved mean sleep latency, reduced daytime sleepiness, and decreased cataplexy rates compared to placebo over 12 weeks, although it was associated with a high incidence of adverse events, particularly increased urinary frequency and transient insomnia.

Treatment Decisions in Multiple Myeloma

Sep 9, 2026

The authors aim to provide a practical framework for navigating treatment decisions in multiple myeloma, addressing the complexities introduced by advancements in therapies and the need for individualized treatment strategies. They emphasize the importance of factors such as cytogenetic and genomic risk stratification, functional fitness, and measurable residual disease status in guiding therapy for newly diagnosed patients and those experiencing relapse. Additionally, the authors advocate for the enrollment of patients in clinical trials to foster ongoing advancements in treatment options.

Tozorakimab to Prevent COPD Exacerbations

Sep 8, 2026

The authors aimed to evaluate the efficacy of tozorakimab, a monoclonal antibody targeting interleukin-33, in reducing the frequency of moderate or severe exacerbations in patients with chronic obstructive pulmonary disease (COPD) who continued to experience exacerbations despite standard inhaled therapy. In two phase 3 trials, results showed that tozorakimab significantly lowered the annualized rate of exacerbations compared to placebo in both former smokers and the overall population. Safety assessments indicated a similar incidence of adverse events between the treatment and placebo groups.

Daraxonrasib for Previously Treated <em>RAS</em>-Mutant Non-Small-Cell Lung Cancer

Sep 2, 2026

The authors aimed to evaluate the safety and efficacy of daraxonrasib, a multiselective inhibitor targeting RAS mutations, in patients with previously treated RAS-mutant non-small-cell lung cancer (NSCLC). In a phase 1-2 study involving 136 patients, they found that 54% experienced grade 3 or higher adverse events, while over 30% showed objective antitumor responses at doses of 300 mg or less. These findings suggest that daraxonrasib has potential therapeutic activity, albeit with significant safety concerns.